Biotech Daily Dose


pharma-020518_14nov18.jpg Today's Daily Dose brings you news about AbbVie's uterine fibroids trial results; Apollo Medical's third quarter financial results; Aldeyra Therapeutics' anticipated milestones; Axsome's progress in its ASCEND trial; BELLUS Health's near-term catalyst, and FDA panel's vote on Mallinckrodt's MNK-812.

weekahead-nov09.jpg Clinical trial data is an important catalyst, and any update on the clinical studies can send the biotech stocks soaring or stumbling depending upon the news. Here are some of the pharma/biotech stocks to watch out for in the week starting November 12.

pharma-021317_07nov18.jpg Today's Daily Dose brings you news about the near-term catalysts of Catalyst Pharma; progress in Entasis' gonorrhea study; positive results of Foamix Pharma's phase III papulopustular rosacea studies; Lannett's revised revenue outlook; NantKwest's cancer vaccine trial results; Nu Skin Enterprises' Q3 financial results and Rennova Health's reverse stock split.

pharma-012517_06nov18.jpg Today's Daily Dose brings you news about Achaogen's corporate restructuring; AVEO Oncology's TIVO-3 trial results; Mirati Therapeutics' near-term catalysts and FDA approval of Theratechnologies' supplemental New Drug Application of Egrifta.

pharma-aug21_01nov18.jpg Today's Daily Dose brings you news about ACADIA's CLARITY trial results; Clovis' lackluster third quarter financial results; CryoLife's revised earnings and revenue outlook for the year; FDA approval of the third Humira biosimilar, and Strongbridge's deal with Novo Nordisk.

pharma-011718_30oct18.jpg Today's Daily Dose brings you news about FDA approval of TherapeuticsMD's BIJUVA; CTD Holdings' patent filing related to methods for treating Alzheimer's disease; Amedisys' third-quarter results and rosy outlook for the year, and Genmab's phase III multiple myeloma study.

pharma-020917_28oct18.jpg Today's Daily Dose brings you news about Anavex's encouraging results from its Alzheimer's study; Esperion's promising phase III clinical development program evaluating the LDL-C-lowering efficacy of bempedoic acid; Grifol's AMBAR trial; Retrophin's long-term data from DUET study, and Ultagenyx's failed glucose transporter type-1 deficiency syndrome (Glut1 DS) trial.

brokenheart-oct26.jpg "Grief is itself a medicine", said William Cowper, a popular English poet. But for some, it can prove fatal. In this week's "Did you know?" column, we are presenting interesting findings about the impact of grief on human health, Marijuana 2.0 in the making, and link between height and cancer risk.

ipo-oct26.jpg Eton Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing ophthalmic products under 505(b)(2) regulatory pathway. Eton is a spin-out company of Imprimis Pharmaceuticals, Inc. (IMMY).

synergy-oct26.jpg Shares of Synergy Pharmaceuticals Inc. (SGYP) slumped over 71% in extended trading on Thursday, following a disappointing business update.

pharma-020117_24oct18.jpg Today's Daily Dose brings you news about Clementia's Palovarotene NDA submission; Dermira's near-term catalyst; promising results of Pfizer and Eli Lilly's phase III study of investigational Tanezumab in patients with osteoarthritis pain, and better-than-expected Q3 financial results of USANA Health.

pharma-011617_23oct18.jpg Today's Daily Dose brings you news about AbbVie's ulcerative colitis trial results; Chembio's preliminary Q3 revenue and stock offering; HealthStream's Q3 results and CFO resignation; Intec Pharma's progress in ACCORDANCE study, and acquisition of Therapix Biosciences by SD Pharma.

pnarmacalander-oct19.jpg Biotech stocks are very volatile as they are driven by clinical trial data and regulatory decisions. Let's take a look at the companies that are scheduled to report/update their clinical trial results this week.

pharma-010918_21oct18.jpg Today's Daily Dose brings you news about BioLineRx's promising phase II pancreatic adenocarcinoma trial results; FDA's new decision date for Bristol-Myers Squibb's Opdivo plus low-dose Yervoy sBLA; Dynavax Technologies' SYNERGY-001 study results; Genmab's promising results from phase III CASSIOPEIA study, and Leap's promising esophagogastric cancer trial results.

ipo-aug13.jpg Alzheon is a U.S. clinical-stage biopharmaceutical company developing medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders.

Follow RTT